Pharmaceutical company NuPathe Inc. out of Conshohocken, PA has just announced positive results from Phase III clinical trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraines. Zelrix relies on the company’s proprietary iontophoretic transdermal technology, called SmartRelief™, to continuously deliver sumatriptan. 
The big idea behind Zelrix, “a thin, disposable, single-use device in a self-contained system,” is to give migraine sufferers a new therapeutic option with a proven medication, so they can stick on a patch and get medication fast and consistently, regardless of nausea, vomiting, or other gastric symptoms associated with migraine.
To learn more about the technology and the product, follow these links:
Press release: NuPathe Reports Positive Phase III Results for Zelrix, a Novel Transdermal Patch For Acute Migraine…
Product page: Zelrix…
Technology page: NuPathe Drug Delivery Platforms…
White paper: NP101: A Novel Formulation of Sumatriptan Succinate Utilizing SmartRelief™ Transdermal Technology (.pdf)
(hat tip: The Medical Quack)
Zelrix, A Migraine Patch, Is Moving Forward
August 14th, 2009 
Medgadget Editors Medicine, Neurology